{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:06Z","timestamp":1791229626815,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81173250"],"award-info":[{"award-number":["81173250"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Radioactive iodine (RAI) therapy is an important treatment option for Graves\u2019 disease (GD), the main side effect of RAI treatment is hypothyroidism, and the factors resulting in hypothyroidism are still controversial. The purpose of this retrospective study was to clarify the possible risk factors of early hypothyroidism after RAI therapy in Graves\u2019 disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed 312 GD patients treated with RAI between January 2017 to December 2018, collected the potential risk factors, and analyzed the relationship between these variables and early hypothyroidism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 6\u2009months\u2019 follow-up, 218 (69.87%) patients were evaluated as early hypothyroid. Male gender, shorter duration of disease, smaller thyroid weight, lower 2-h radioactive iodine uptake (RAIU), 6-h RAIU, 24-h RAIU and 6\/24-h uptake ratio, lower administered dosages were significantly associated with early hypothyroidism. Logistics regression analysis showed that male gender, smaller thyroid weight and lower 6-h RAIU were associated with early hypothyroidism. Multi-factors combined ROC curve analysis suggested that the predictive power of male gender, smaller thyroid weight and lower 6-h RAIU for early hypothyroidism was 0.711.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results show that RAI is an effective therapy for GD and most of the cured patients became to hypothyroid within 6\u2009months. Male gender, smaller thyroid weight and lower 6-h RAIU are the main risk factors for early hypothyroidism.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12902-020-00557-w","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T13:03:08Z","timestamp":1590757388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves\u2019 disease patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Rui-Ting","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-3284","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"issue":"16","key":"557_CR1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Longo DL, Heged\u00fcs L. Graves\u2019 disease. N Engl J Med. 2016;375(16):1552\u201365.","journal-title":"N Engl J Med"},{"issue":"3","key":"557_CR2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12020-017-1306-5","volume":"56","author":"YS Hussain","year":"2017","unstructured":"Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of graves\u2019 disease\u2014real life data. Endocrine. 2017;56(3):568\u201378.","journal-title":"Endocrine"},{"issue":"10","key":"557_CR3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","volume":"27","author":"F Azizi","year":"2017","unstructured":"Azizi F, Malboosbaf R. Long-term Antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017;27(10):1223\u201331.","journal-title":"Thyroid"},{"issue":"1","key":"557_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3803\/EnM.2019.34.1.29","volume":"34","author":"WM Wiersinga","year":"2019","unstructured":"Wiersinga WM. Graves' disease: can it be cured? Endocrinol Metab. 2019;34(1):29.","journal-title":"Endocrinol Metab"},{"issue":"11","key":"557_CR5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1089\/thy.2019.0085","volume":"29","author":"G Sj\u00f6lin","year":"2019","unstructured":"Sj\u00f6lin G, Holmberg M, T\u00f6rring O, Bystr\u00f6m K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B, et al. The long-term outcome of treatment for Graves' hyperthyroidism. Thyroid. 2019;29(11):1545\u201357.","journal-title":"Thyroid"},{"issue":"9821","key":"557_CR6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(11)60782-4","volume":"379","author":"JA Franklyn","year":"2012","unstructured":"Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155\u201366.","journal-title":"Lancet"},{"issue":"9","key":"557_CR7","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2013-1954","volume":"98","author":"V Sundaresh","year":"2013","unstructured":"Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"557_CR8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","volume":"41","author":"E Masiello","year":"2018","unstructured":"Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, et al. Antithyroid drug treatment for graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Investig. 2018;41(12):1425\u201332.","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"557_CR9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/thy.2016.0343","volume":"27","author":"V Sundaresh","year":"2017","unstructured":"Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid. 2017;27(4):497\u2013505.","journal-title":"Thyroid"},{"issue":"1","key":"557_CR10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13873","volume":"90","author":"ET Aung","year":"2019","unstructured":"Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in graves\u2019 thyrotoxicosis. Clin Endocrinol. 2019;90(1):192\u20139.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"557_CR11","first-page":"64","volume":"22","author":"J Li","year":"2019","unstructured":"Li J, Zhang L, Zhang Z, Liu J, Zhang H, Lin X, Jiang N. Factors suggesting relapse of Grave's disease after first radioiodine therapy. Analysis of 607 cases. Hell J Nucl Med. 2019;22(1):64\u20139.","journal-title":"Hell J Nucl Med"},{"key":"557_CR12","doi-asserted-by":"crossref","unstructured":"Xing YZ, Zhang K, Jin G. Predictive factors for the outcomes of Graves\u2019 disease patients with radioactive iodine (131I) treatment. Biosci Rep. 2019;40(1).","DOI":"10.1042\/BSR20191609"},{"issue":"6","key":"557_CR13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0b013e3182817c78","volume":"38","author":"JA de Jong","year":"2013","unstructured":"de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B. High failure rates after (131) I therapy in graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med. 2013;38(6):401\u20136.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"557_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MNM.0b013e32834d3bb9","volume":"33","author":"W Zheng","year":"2012","unstructured":"Zheng W, Jian T, Guizhi Z, Zhaowei M, Renfei W. Analysis of 131i therapy and correlation factors of graves\u2019disease patients. Nucl Med Commun. 2012;33(1):97\u2013101.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"557_CR15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","volume":"88","author":"WD Leslie","year":"2003","unstructured":"Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"557_CR16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, et al. 2016 American Thyroid Association guidelines for diagnosis and Management of Hyperthyroidism and Other Causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421.","journal-title":"Thyroid"},{"issue":"12","key":"557_CR17","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","volume":"97","author":"HB Burch","year":"2012","unstructured":"Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012;97(12):4549\u201358.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"557_CR18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","volume":"84","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol. 2016;84(1):115\u201320.","journal-title":"Clin Endocrinol"},{"key":"557_CR19","doi-asserted-by":"crossref","unstructured":"Seib CD, Chen J, Iagaru A. Shifting trends and informed decision making in the Management of Graves' disease. Thyroid. 2020.","DOI":"10.1089\/thy.2020.0114"},{"issue":"1","key":"557_CR20","first-page":"40","volume":"83","author":"L Chiovato","year":"1998","unstructured":"Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"557_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2362.2004.01349.x","volume":"34","author":"MA Walter","year":"2004","unstructured":"Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Muller-Brand J, Muller B. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Investig. 2004;34(5):365\u201370.","journal-title":"Eur J Clin Investig"},{"issue":"4","key":"557_CR22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02984622","volume":"19","author":"M Nakajo","year":"2005","unstructured":"Nakajo M, Tsuchimochi S, Tanabe H, Nakabeppu Y, Jinguji M. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy. Ann Nucl Med. 2005;19(4):297\u2013308.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"557_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4274\/Mirt.08370","volume":"22","author":"MJ Enyi Ejeh","year":"2013","unstructured":"Enyi Ejeh MJ, Omotayo Ogunjobi K, Enyi Ejeh J, Solomon Adedapo K. J FE: effectiveness of fixed dose radioactive iodine (RAI) for the treatment of hyperthyroidism: experience of a teaching hospital in south West Nigeria. Mol Imaging Radionucl Ther. 2013;22(2):36\u201341.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"4","key":"557_CR24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5455\/medarh.2017.71.270-273","volume":"71","author":"N Beslic","year":"2017","unstructured":"Beslic N, Licina S, Sadija A, Milardovic R. Incidence of Hypothyreoidism after radioactive iodine-I131 treatment in Dependance of Hyperthyreoidism etiology and therapy dose. Med Arch. 2017;71(4):270\u20133.","journal-title":"Med Arch"},{"issue":"6","key":"557_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.47102\/annals-acadmedsg.V48N6p181","volume":"48","author":"WL Tay","year":"2019","unstructured":"Tay WL, Chng CL, Tien CS, Loke KS, Lam WW, Fook-Chong SM, Tong AK. High thyroid stimulating receptor antibody titre and large goitre size at first-time radioactive iodine treatment are associated with treatment failure in Graves' disease. Ann Acad Med Singap. 2019;48(6):181\u20137.","journal-title":"Ann Acad Med Singap"},{"issue":"9\u201310","key":"557_CR26","first-page":"450","volume":"10","author":"CC Alevizaki","year":"1985","unstructured":"Alevizaki CC, Alevizaki-Harhalaki MC, Ikkos DG. Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur J Nucl Med. 1985;10(9\u201310):450\u20134.","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"557_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2265.2008.03291.x","volume":"70","author":"K Boelaert","year":"2009","unstructured":"Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol. 2009;70(1):129\u201338.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"557_CR28","first-page":"432","volume":"13","author":"WMI Wan Mohamed","year":"2018","unstructured":"Wan Mohamed WMI, Sayuti SC, Draman N. Hypothyroidism and its associated factors after radioactive iodine therapy among patients with hyperthyroidism in the northeast coast state of Malaysia. J Taibah Univ Med Sci. 2018;13(5):432\u20137.","journal-title":"J Taibah Univ Med Sci"},{"issue":"1","key":"557_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MNM.0000000000000770","volume":"39","author":"D Yang","year":"2018","unstructured":"Yang D, Xue J, Ma W, Liu F, Fan Y, Rong J, Yang A, Yu Y. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy. Nucl Med Commun. 2018;39(1):16\u201321.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"557_CR30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLU.0000000000000840","volume":"40","author":"MT Sapienza","year":"2015","unstructured":"Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric variables related to outcome after treatment of Graves' disease with 550 and 1110 MBq of 131I: results of a prospective randomized trial. Clin Nucl Med. 2015;40(9):715\u20139.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"557_CR31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/MNM.0000000000000285","volume":"36","author":"D Sfiligoj","year":"2015","unstructured":"Sfiligoj D, Gaberscek S, Mekjavic PJ, Pirnat E, Zaletel K. Factors influencing the success of radioiodine therapy in patients with Graves' disease. Nucl Med Commun. 2015;36(6):560\u20135.","journal-title":"Nucl Med Commun"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00557-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-020-00557-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00557-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:14:36Z","timestamp":1666718076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00557-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00557-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of Linyi People\u2019s Hospital Affiliated to Shandong University and was performed in accordance with the guidelines and regulations. Informed written consent was obtained from the all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no competing interests regarding the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}